Debiopharm and Takeda collaborate on the development of therapies for gastrointestinal disorders
Life sciences
16 June 2020
Pharmaceutical company Debiopharm has concluded a licensing agreement with Takeda for its new microbiome remodeling program for the treatment of gastrointestinal disorders. Partly based in Martigny in the canton of Valais, Debiopharm has concluded an agreement with Japanese research leader Takeda. This exclusive license and research collaboration agreement with Takeda Pharmaceutical Company Limited will be […]
Pharmaceutical company Debiopharm has concluded a licensing agreement with Takeda for its new microbiome remodeling program for the treatment of gastrointestinal disorders.
Partly based in Martigny in the canton of Valais, Debiopharm has concluded an agreement with Japanese research leader Takeda. This exclusive license and research collaboration agreement with Takeda Pharmaceutical Company Limited will be used for the development of new microbiomic therapies for the treatment of gastrointestinal disorders..
Under the agreement, Takeda will screen and optimize compounds derived from Debiopharm’s discovery Debio 1454M program to identify candidates for further development for the treatment of inflammatory bowel disease (IBD) and other GI disorders.
These products are intended to treat chronic gastrointestinal inflammatory diseases, such as Crohn’s disease or ulcerative colitis, both of which are very serious diseases. The process thus initiated may allow the validation of a series of molecules from Debiopharm’s antibacterial programs.
A genuine breakthrough for patients
“This program could represent a genuine breakthrough for patients, while minimizing the emergence of resistance thanks to its targeted mode of action,” explains Bertrand Ducrey, CEO of Debiopharm. Debiopharm’s teams will continue to be involved in the development and governance of the partnership.
As a general rule, the Valais-based company will only enter into a partnership when it considers that other companies can bring genuine added value to the project. “With Takeda, we can go beyond treating the symptoms of gastrointestinal diseases and tackle the imbalances in the microbiome that would cause them,” concludes Bertrand Ducrey.
